Explorando el poder de los abordajes transcriptómicos para identificar biomarcadores asociados a daño renal en pacientes con lupus eritematoso sistémico
Cargando...
Archivos
Fecha
2021
Autores
Arrieta Bravo, Valentina
Rangel Gómez, Tiffany
Pacheco Lugo, Lisandro
Título de la revista
ISSN de la revista
Título del volumen
Editor
Asociación Colombiana de Nefrología e hipertensión Arterial
Facultad de Ciencias de la Salud
Facultad de Ciencias de la Salud
Resumen
El lupus eritematoso sistémico (LES) es una enfermedad compleja y altamente heterogénea que
afecta múltiples órganos, incluyendo articulaciones, corazón, sistema hematopoyético, sistema
nervioso y riñón, siendo este último el de peor pronóstico y el que conlleva a nefritis lúpica (NL).
Aunque la etiopatogénesis del LES aún no se conoce con claridad, se cree que la susceptibilidad
genética y las modificaciones epigenéticas aberrantes favorecen su desenlace. Para establecer una
terapia precisa es necesario evaluar de manera eficiente y objetiva el compromiso de órganos y
la actividad de la enfermedad, lo cual es muy difícil por las pocas pruebas de laboratorio clínico
disponibles en la actualidad.
En las últimas décadas la búsqueda de nuevos biomarcadores de LES ha sido una tendencia y se
han identificado varios promisorios a nivel de genómica, metabolómica, proteómica y transcriptómica. En esta revisión se resume el estado del arte relacionado con estudios transcriptómicos
que han identificado diversos transcritos potencialmente útiles como biomarcadores del LES y la
NL
Systemic Lupus Erythematosus is a complex and highly heterogeneous disease affecting multiple organs such as joints, heart, hematopoietic system, nervous system and kidney, the latter being the worst prognosis and leading to lupus nephritis (LN). While the etiopathogenesis of SLE is still not completely clear, is believed that genetic susceptibility and aberrant epigenetic modifications favor the outcome of the disease. In order to establish an accurate therapy, it is necessary to efficiently and objectively assess organ involvement and disease activity, which is very dificult due to the clinical laboratory tests currently available. In recent decades, the search for new SLE biomarkers has been a trend and many promising biomarkers have been identified at the genomic, metabolomic, proteomic and transcriptomic levels. In this review we summarize the state of the art related to transcriptomic studies that have identified various potentially useful transcripts as biomarkers of SLE and NL.
Systemic Lupus Erythematosus is a complex and highly heterogeneous disease affecting multiple organs such as joints, heart, hematopoietic system, nervous system and kidney, the latter being the worst prognosis and leading to lupus nephritis (LN). While the etiopathogenesis of SLE is still not completely clear, is believed that genetic susceptibility and aberrant epigenetic modifications favor the outcome of the disease. In order to establish an accurate therapy, it is necessary to efficiently and objectively assess organ involvement and disease activity, which is very dificult due to the clinical laboratory tests currently available. In recent decades, the search for new SLE biomarkers has been a trend and many promising biomarkers have been identified at the genomic, metabolomic, proteomic and transcriptomic levels. In this review we summarize the state of the art related to transcriptomic studies that have identified various potentially useful transcripts as biomarkers of SLE and NL.
Descripción
Palabras clave
Lupus eritematoso sistémico, Nefritis lúpica, Biomarcadores, MicroARNs, Systemic lupus erythematosus, Lupus nephritis, Biomarkers, MicroRNAs
